

Table 14.2/1
Progression-Free Survival by Remission Status
Randomized Subjects

--								
			-2nd remission-		-3rd remission-		-Overall-	
			Placebo (N= 26)	CMP_135 (N= 26)	Placebo (N= 6)	CMP_135 (N= 7)	Placebo (N= 32)	CMP_135 (N= 33)
.	.	No.of subjects	26	26	6	7	32	33
.	.	No.of subjects with an event (%)	15(57.7%)	12(46.2%)	3(50.0%)	3(42.9%)	18(56.3%)	15(45.5%)
.	.	Ealiest Contributing event						
.	.	DISEASE PROGRESSION	15	12	3	3	18	15
.	.	No.of subjects without an event (%)	11(42.3%)	14(53.8%)	3(50.0%)	4(57.1%)	14(43.8%)	18(54.5%)
.	.							
.	.	Progression_Free survival (month)						
.	.	Median	5.6	7.7	7.4	5.6	5.8	7.7
.	.	(95% CI)	(3.78, 7.43)	(5.59, NA)	(2.07, NA)	(3.48, NA)	(3.88, 7.43)	(5.59, NA)
.	.	25th - 75th percentile	3.6-NA	5.3-13.3	5.8-NA	5.6-NA	3.6-NA	5.6-13.3
.	.	Minimum- maximum	0.8-9.2 +	1.1-13.3 +	2.1-12.9 +	1.9-9.2 +	0.8-12.9 +	1.1-13.3 +
.	.							
.	.	Unstratified analysis						
.	.	p-value(relative to placebo)						
.	.	Log-Rank		0.2890		0.8440		0.3857
.	.	Wilcoxon		0.3815		0.7768		0.4234
.	.							
.	.	Stratified analysis						
.	.	Hazard ratio (relative to placebo)						0.730
.	.	(95% CI)						(0.444,1.201)
.	.	p-value(relative to placebo)						
.	.	Log-Rank						0.7282
.	.	Wilcoxon						0.6569